Rachel Narozniak, MA | Authors

November 16, 2020

Positive preliminary data from the phase 1 DUET-1 study examining XmAb18087 in patients with neuroendocrine tumors demonstrated promising safety and efficacy findings.

May 31, 2020

"Irrespective of the PD-L1 status, there were no trends in favor of atezolizumab in both arms."

May 30, 2020

The long-term benefit of adjuvant dabrafenib plus trametinib as treatment of patients with resected, stage III BRAF V600E/K-mutant melanoma were validated by 5-year data from the phase 3 COMBI-AD study.

March 21, 2020

Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

November 12, 2019

In a presentation describing the utility of circulating tumor DNA liquid biopsy assays at the 14th Annual New York Lung Cancers Symposium, Bob T. Li, MD, MPH, said that plasma genotyping demsonstrates practice-changing potential in non–small cell lung cancer.

November 10, 2019

According to Tina Cascone, MD, PhD, in a presentation during the 14th Annual New York Lung Cancers Symposium, neoadjuvant immunotherapy is under investigation for patients with non–small cell lung cancer and holds hope as a treatment for patients.